title: Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents.
abstract: Advances in the understanding of genetic engineering, protein expression, and Ig function have come together to allow for the rapid synthesis and production of a novel generation of potent immunomodulating reagents. Selective approaches that allow the isolation of desired specificities will be elucidated through meticulous engineering techniques. This, in turn, may eventually result in the fulfillment of the tremendous potential of engineered proteins for therapeutic and diagnostic applications.
authors.affiliation: Harvard Medical School, Division of Immunology Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
authors.forename: Y S
authors.initials: YS
authors.lastname: Kim
authors.forename: W
authors.initials: W
authors.lastname: Maslinski
authors.forename: X X
authors.initials: XX
authors.lastname: Zheng
authors.forename: A D
authors.initials: AD
authors.lastname: Schachter
authors.forename: T B
authors.initials: TB
authors.lastname: Strom
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016207:Cytokines / Q000235:genetics / Q000627:therapeutic use; D005818:Genetic Engineering / Q000379:methods; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000922:Immunotoxins / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins